.Pharmacolibrary.Drugs.ATC.L.L01CA02 .Pharmacolibrary.Drugs.ATC.L.L01CA02| name: | Vincristine |
| ATC code: | L01CA02 | route: | intravenous |
| n-compartments | 3 |
Vincristine is a vinca alkaloid chemotherapeutic agent approved for use in the treatment of various malignancies including acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Wilms' tumor, neuroblastoma, and rhabdomyosarcoma. It is not used for solid tumors. Vincristine interferes with microtubule formation and mitosis.
Pharmacokinetic parameters reported for adult cancer patients; sex: both; typical intravenous dosing as a bolus.
van de Velde, ME, et al., & Kaspers, GL (2020). Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers 12(7) –. DOI:10.3390/cancers12071789 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32635465
Gota, V, et al., & Menon, H (2016). Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer chemotherapy and pharmacology 78(2) 353–359. DOI:10.1007/s00280-016-3083-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/27329361
Davies, A, et al., & Macdonald, D (2014). Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet. Oncology 15(3) 343–352. DOI:10.1016/S1470-2045(14)70005-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24521993